FLT3 inhibitor
FLT3 tyrosine kinase inhibitor
- ↓ FLT3-driven proliferation in FLT3-mutant AML
- ITD and TKD mutations differ in which inhibitors retain activity
- Class effect: QT prolongation — correct potassium and magnesium before and during
Drugs with this mechanism (1)
- Quizartinib — FLT3 inhibitor used with chemotherapy for newly diagnosed FLT3-ITD-positive AML; substantial QT-prolongation risk requires monitoring.
Self-check
- Do FLT3 ITD and TKD mutations respond identically to inhibitors?
No; retained activity differs by mutation. - Which electrolytes should be corrected before and during FLT3-inhibitor treatment?
Potassium and magnesium, because of QT prolongation.
All mechanisms · Open FLT3 inhibitor in the interactive console ↗